Literature DB >> 25788241

Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.

Manpreet Kaur1, Kavita M Gupta, Azadeh E Poursaid, Prasoona Karra, Alamelu Mahalingam, Hyder A Aliyar, Patrick F Kiser.   

Abstract

We describe the engineering of a degradable intravaginal ring (IVR) for the delivery of the potent HIV-1 reverse transcriptase inhibitor dapivirine. The degradable polymer used in fabricating the device incorporated poly(caprolactone) ester blocks in a poly(tetramethylene ether) glycol ABA type polyurethane backbone. The polymer was designed to maintain its structure for 1 month during usage and then degrade in the environment post-disposal. In vitro release of dapivirine showed zero-order kinetics for up to 1 month and significant levels of drug release into engineered vaginal tissue. The mechanical properties of the degradable IVR were comparable to those of a widely used contraceptive intravaginal ring upon exposure to simulated vaginal conditions. Incubation under simulated vaginal conditions for a month caused minimal degradation with minimal effect on the mechanical properties of the ring and polymer. The cytotoxicity evaluation of the drug-loaded IVRs against Vk2/E6E7 human vaginal epithelial cells, Lactobacillus jensenii, and engineered vaginal tissue constructs showed the degradable polyurethane to be non-toxic. In vitro evaluation of inflammatory potential monitored through the levels of inflammatory cytokines IL-8, IL-1α, IL-6, IL-1β, and MIP-3α when engineered EpiVaginal™ tissue was incubated with the polyurethanes suggested that the degradable polyurethane was comparable to commercial medical grade polyurethane. These results are encouraging for further development of this degradable IVR for topical vaginal delivery of microbicides.

Entities:  

Year:  2011        PMID: 25788241     DOI: 10.1007/s13346-011-0027-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  39 in total

1.  A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring.

Authors:  E Weisberg; I S Fraser; J Baker; D Archer; B M Landgren; S Killick; P Soutter; T Krause; C d'Arcangues
Journal:  Contraception       Date:  2000-08       Impact factor: 3.375

Review 2.  Microbicides: a new approach to preventing HIV and other sexually transmitted infections.

Authors:  Alan Stone
Journal:  Nat Rev Drug Discov       Date:  2002-12       Impact factor: 84.694

3.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

4.  Rural women's knowledge of AIDS in the higher prevalence states of India: reproductive health and sociocultural correlates.

Authors:  Saseendran Pallikadavath; Abdoulie Sanneh; Jenny M McWhirter; R William Stones
Journal:  Health Promot Int       Date:  2005-03-29       Impact factor: 2.483

5.  The future of HIV prevention: prospects for an effective anti-HIV microbicide.

Authors:  Jeremy Nuttall; Joseph Romano; Karen Douville; Caroline Galbreath; Annaléne Nel; William Heyward; Mark Mitchnick; Saul Walker; Zeda Rosenberg
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

6.  The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.

Authors:  R N Fichorova; L D Tucker; D J Anderson
Journal:  J Infect Dis       Date:  2001-07-16       Impact factor: 5.226

7.  Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

Authors:  A David Woolfson; R Karl Malcolm; Ryan J Morrow; Clare F Toner; Stephen D McCullagh
Journal:  Int J Pharm       Date:  2006-06-23       Impact factor: 5.875

8.  Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring.

Authors:  W Bounds; A Szarewski; D Lowe; J Guillebaud
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1993-02       Impact factor: 2.435

9.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

10.  Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.

Authors:  J Romano; B Variano; P Coplan; J Van Roey; K Douville; Z Rosenberg; M Temmerman; H Verstraelen; L Van Bortel; S Weyers; M Mitchnick
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

View more
  9 in total

1.  An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Authors:  Shweta R Ugaonkar; Justin T Clark; Lexie B English; Todd J Johnson; Karen W Buckheit; Robert J Bahde; Daniel H Appella; Robert W Buckheit; Patrick F Kiser
Journal:  J Pharm Sci       Date:  2015-07-06       Impact factor: 3.534

2.  Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

Authors:  Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold
Journal:  J Antimicrob Chemother       Date:  2012-03-30       Impact factor: 5.790

3.  Preparation and performance of chlorfenapyr microcapsules with a degradable polylactide-based polyurethane wall material.

Authors:  Linfang Zhu; Guangqi Jiang; Jun Cen; Linhuai Li
Journal:  RSC Adv       Date:  2022-06-07       Impact factor: 4.036

4.  Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli.

Authors:  Yannick Leandre Traore; Yufei Chen; Anne-Marie Bernier; Emmanuel A Ho
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

5.  Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginalTM Tissue Model.

Authors:  May Wenche Jøraholmen; Pauliina Damdimopoulou; Ganesh Acharya; Nataša Škalko-Basnet
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

Review 6.  The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings.

Authors:  Louise Carson; Ruth Merkatz; Elena Martinelli; Peter Boyd; Bruce Variano; Teresa Sallent; Robert Karl Malcolm
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

7.  Vaginal rings for delivery of HIV microbicides.

Authors:  R Karl Malcolm; Susan M Fetherston; Clare F McCoy; Peter Boyd; Ian Major
Journal:  Int J Womens Health       Date:  2012-11-20

Review 8.  Sustained Release Drug Delivery Applications of Polyurethanes.

Authors:  Michael B Lowinger; Stephanie E Barrett; Feng Zhang; Robert O Williams
Journal:  Pharmaceutics       Date:  2018-05-09       Impact factor: 6.321

Review 9.  In Vitro Methods for Evaluating Drug Release of Vaginal Ring Formulations-A Critical Review.

Authors:  Katharina Tietz; Sandra Klein
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.